Keywords: eisai, regains, rights, antifungal, b-ms, japan, terminated

Eisai regains rights to antifungal from B-MS

Article | 08 November 2004

Japan's Eisai has terminated a licensing agreement with US drug major Bristol-Myers Squibb for its antifungal agent, ravuconazole. The Japanese ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Eisai

Go to company listing